FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 186 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC MOST POPULAR FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... February 6, 2025 Pembrolizumab Combinations Show Promise in mCRPC November 21, 2020 Studying Genes and Proteins Together Sheds New Light on Colon Cancer May 28, 2019 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Load more HOT NEWS Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma EMA Recommends Granting a Marketing Authorisation for Tepotinib Ifosfamide May Be Treatment of Choice for Some People with Ewing...
